Tag : ROMOSOZUMAB

The 48-month extended analysis demonstrated greater gains in bone mineral density (BMD) with sequential romosozumab followed by denosumab compared with denosumab alone in long-term glucocorticoid users at high fracture risk. These findings were sustained across the lumbar spine and hip, with significant improvements in spinal trabecular bone score also observed with sequential treatment.
